ARTICLE | Company News
Enchira, University of Texas M.D. Anderson Cancer Center deal
October 16, 2000 7:00 AM UTC
The partners will develop ligands that block epidermal growth factor receptors. ENBC will use its directed evolution technology to create ligands that suppress overexpression of the EGFR and HER-2/ne...